

JL 4/29/02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of: Brian R. Murphy et al.

RECEIVED

APR 10 2002

Group Art Unit: 1642

TECH CENTER 1600/2900

Examiner: B. Brumback


Serial No.: 09/444,221

Filing Date: November 19, 1999

For: PRODUCTION OF ATTENUATED RESPIRATORY SYNCYTIAL VIRUS
VACCINES FROM CLONED NUCLEOTIDE SEQUENCES

DATE OF DEPOSIT: March 25, 2002
 I HEREBY CERTIFY THAT THIS PAPER IS BEING
 DEPOSITED WITH THE UNITED STATES POSTAL SERVICE
 AS FIRST CLASS MAIL, POSTAGE PREPAID ON THE DATE
 INDICATED ABOVE AND IS ADDRESSED TO THE
 COMMISSIONER FOR PATENTS AND TRADEMARKS,
 WASHINGTON, DC 20231

TYPED NAME: Jeffrey J. King
 REGISTRATION NO.: 38,515



Assistant Commissioner for Patents
 Washington, DC 20231

Sir:

AMENDMENT/RESPONSE

In response to the Office Action dated September 25, 2001 (Paper No. 12), please amend the above-identified application as follows:

Please amend the claims as follows:

90. (Amended) The recombinant RSV of claim 63, wherein a modification is introduced within the recombinant genome or antigenome comprising a partial or complete gene deletion, a change in gene position, or one or more nucleotide change(s) that modulate expression of a selected gene.

101. (Amended) The recombinant RSV of claim 100, wherein the recombinant genome or antigenome is further modified to incorporate at least one and up to a full complement of attenuating mutations present within a panel of biologically derived mutant human RSV strains, said panel comprising cpts RSV 248 (ATCC VR 2450), cpts RSV 248/404 (ATCC VR 2454), cpts RSV 248/955 (ATCC VR 2453), cpts RSV 530 (ATCC VR 2452), cpts RSV